Y PET/CT, which means the possibility of underestimation of tumorous uptake in the partition dosimetry model using 99m Tc MAA SPECT. Considering that 99m Tc MAA is the only clinically available surrogate marker for distribution of microsphere, we recommend measurement of tumorous uptake using 90 Y PET/CT should be included routinely in the posttherapeutic evaluation.
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Introduction
Yttrium-90 ( 90 Y) microsphere transarterial radioembolization (TARE) is an alternative therapy option for unresectable liver malignancies, including primary and metastatic diseases. It is also considered a tool for bridging to resection, radiofrequency ablation, and liver transplantation [1] . Several reports have shown that TARE could be beneficial in the management of advanced liver malignancy [2] [3] [4] [5] .
Technetium-99m ( 99m Tc) macroaggregated albumin (MAA) liver breakthrough imaging is a tool used for the evaluation of intrahepatic and possible extrahepatic distribution and for the estimation of lung shunt fraction. The intrahepatic tracer distribution and tumor-to-normal uptake ratio (TNR) are important for dose calculation especially when using a partition model. Many reports have suggested the correlation of 99m Tc MAA dosimetry and intraoperative estimation of radiation doses [6] [7] [8] [9] [10] [11] . After the injection of the microsphere, postembolization evaluation for the distribution of 90 Y microspheres is essential to predict possible complications and treatment response [12] . Bremsstrahlung imaging and/or SPECT of 90 Y microspheres is useful not only for the evaluation of posttreatment distribution of microspheres in the liver target volume, but also for the evaluation of possible extrahepatic spillage. The poor spatial resolution of the 90 Y microsphere bremsstrahlung image (FWHM 12.5 mm-20 mm) and long acquisition time and reconstruction, however, are major limitations for reliable posttreatment evaluation [13] [14] [15] [16] .
Recent studies report the feasibility of high-resolution Y PET/CT [17] [18] [19] . The characteristics of 99m Tc MAA used in treatment planning differ from those of the 90 Y microspheres used in the actual treatment [20] . Some researchers reported that the distributions of microspheres between 99m Tc MAA and 90 Y microspheres are not identical. It has not been fully clarified whether 99m Tc MAA SPECT accurately represents the true delivered 90 Y microsphere distribution [21] . In spite of this limitation, 99m Tc MAA SPECT is the only possible method to evaluate the pretreatment dose distribution and therapy planning. Therefore, it would be important to compare and evaluate the correlation between pretreatment 99m Tc MAA SPECT and highresolution posttreatment images that can show the actual distribution of microspheres.
The purpose of this study is to compare the tumor-tonormal uptake ratios between 99m Tc MAA SPECT pretreatment images and posttreatment 90 Y PET/CT images by semiquantitative comparison to evaluate whether the 99m Tc MAA SPECT image can accurately predict the posttreatment distribution of microspheres.
Materials and Methods

Patients
We retrospectively reviewed the medical records of 52 consecutive patients who had undergone 90 Y microsphere TARE because of unresectable hypervascular hepatocellular carcinoma or metastatic tumors from January 2010 to December 2012. Only patients with preserved hepatic function, ChildPugh score A or B, were included. Patients who presented with extrahepatic metastasis, hepatic failure, previous history of external beam radiation, or systemic chemotherapy were excluded. The ethics review boards of our hospital approved this retrospective study.
Pretreatment Planning Angiography
Pretreatment planning angiography was performed on all patients using the transfemoral approach for celiac, superior mesenteric, and selective hepatic arteriography and was done by an interventional radiologist. For preventing possible extrahepatic arterial spillage, coil embolization was performed in the gastroduodenal, right gastric artery and/or the cystic artery if a significant opportunity for the reflux and escape of microspheres into the GI tract, gall bladder, and pancreas could be considered. Subsequent CT scanning was performed while the intraarterial catheter was in place with injection of contrast media, and tumor and nontumor liver volumes were obtained using hepatic angiography CT images. Thereafter, 100-150 MBq of 99m Tc MAA was injected via the planned target hepatic artery. If the target tumor was located in a segment, the artery corresponding to the segment was chosen as a planned target artery. Tc MAA injection through the planned target artery, patients were brought to the nuclear medicine department and underwent an 99m Tc MAA breakthrough image. We used a dual-head gamma camera (Infinia; GE Healthcare, Milwaukee, WI, USA) with low-energy, high-resolution collimators. The energy window was set at 140±10 keV, and 120-s planar images were acquired for anterior and posterior projections. For the SPECT, 90 projections of the step-and-shoot mode in a 256×256 matrix were acquired in 360 degrees (10 s per step). The SPECT was analyzed on a dedicated Xeleris workstation (GE Healthcare, Milwaukee, WI, USA). We displayed the 99m Tc MAA SPECT images in transverse, sagittal, and coronal format. The slice thickness of the transverse slice was 5 mm.
We evaluated the lung shunt, extrahepatic distribution, and tumor-to-normal liver ratio using a planar image for dose calculation with a partition model. Administration doses were calculated to achieve a tumoricidal dose of 120 Gy.
Y Microsphere Administration and PET/CT Imaging
A resin microsphere (SIR-Sphere, SIRTeX™, Sydney, Australia) was used as the medium of 90 Y. Within 24 h after microsphere administration, the patients were scanned using a PET/CT scanner (Gemini TF PET/CT, Philips Healthcare) with a conventional 18 F energy window (511 keV) and timeof-flight (TOF) mode including attenuation correction. According to the liver size of the patient, one or two imaging bed positions were selected. The imaging time was 10 min per bed. Reconstruction was performed with a TOF orderedsubset expectation maximization iterative (OSEM) algorithm at a 3-iteration and 33-subset protocol. Low-dose CT was used for attenuation correction of the PET emission data.
Image Analysis
We measured the tumor volume by using hepatic angiographic CT. Because we did not use an integrated SPECT/CT machine, the exact registration of tumor 99m Tc MAA uptake with anatomical images is a major concern in this study. The identification of the location of tumor uptake in 99m
Tc MAA SPECT was compared with the latest anatomical images, such as liver CT or MRI, by comparing the images slice by slice. The ratios of the tumor-to-normal liver parenchymal radioactivity uptake count were measured with 90 Y PET/CT (TNR-yp) and 99m Tc MAA SPECT (TNR-ms), respectively. TNR values were calculated by dividing the mean count of the tumorous volume of interest (VOI) by the mean count of normal liver. To measure the radioactivity of a tumor, we manually drew a 2-cm-diameter spherical VOI on the highest uptake portion of the target tumor and calculated a mean count value. Radioactivity of normal liver parenchyma was obtained from the mean value of two or three spherical VOIs of 2 cm diameter at the same lobe with the tumor. Selection of the normal parenchymal count was done by placing VOIs at the proximity of the tumor (Fig. 1) .
To minimize the subjectivity of selecting the normal parenchymal regions and interobserver variation, two researchers independently selected VOIs and measured TNR in 20 randomly selected patients, and we compared the kappa values. 
Results
A total of 52 patients and 79 lesions were evaluated. Hepatocellular carcinoma (HCC) was the most frequent diagnosis (n=42, 81 %). Other diagnoses included cholangiocarcinoma (n=3, 5.8 %), metastasis from colon cancer (n=4, 7.7 %), adrenal cancer (n=1), prostate cancer (n=1), and neuroendocrine tumor (n=1) ( Table 1 ). The data regarding the treated lesions are presented in Table 2 .
The median TNR-yp was 2.78 with an interquartile range of 2.43, and the median TNR-ms was 2.49 with an interquartile range of 1.55. Significant correlation was observed with a moderate Spearman's rho value of 0.648 (p value<0.001) between the TNR-yp and TNR-ms (Fig. 2) . The TNR-yp showed a significantly higher value than that of TNR-ms (p value=0.0118) (Fig. 3) .
The median tumor volume was 187 ml with an interquartile range of 423.75 ml ( Table 2 ). The TNR-yp of 90 Y PET/CT showed borderline correlation with tumor volume measured using angiographic CT (rho=0.230, p value=0.0412) (Fig. 4) . 
Discussion
The role of the pretreatment imaging modality in the radioembolization is to simulate the distribution of the microsphere. An 99m Tc MAA breakthrough scan can be used as a surrogate marker of the 90 Y microsphere [22, 23] . Furthermore, it can predict treatment response. Garin et al. [24] Tc MAA SPECT/CT is useful for predicting the prognosis after 90 Y microsphere treatment. When a higher TNR is observed in 99m Tc MAA SPECT/CT, the patient would show a better response, progression-free survival, and overall survival than those of the patients that have a lower TNR. 90 Y bremsstrahlung scintigraphy is a well-established method and can be easily performed after radioembolization [25] . When combined with SPECT imaging, bremsstrahlung SPECT/CT showed more accurate anatomical localization of 90 Y microspheres [26] . In spite of these characteristics of the bremsstrahlung image, the major drawbacks are the low spatial resolution and long image acquisition time, which would lead to lower tumor-to-normal ratios compared to the 99m Tc MAA images [27] . Moreover, Tc MAA SPECT, with a moderate Spearman's rho value of 0.648. We suggest two possible explanations for this. First, the positron imaging has a lower scatter effect than the SPECT images so that the PET image has a lower background activity [15] . Second, the particle characteristics of the Tc MAA particles have diameters in the range of 15 to 30 μm and a density of 1.3 g/cc, whereas 90 Y microspheres have diameters of 35±5 μm and densities of 1.6 g/cc [31] . The larger size particles would lead to embolization of more proximal vessels and the smaller size particles would preferentially deposit in more distal regions, i.e., more proximity to the tumors [32] . Therefore, a wide variation of particle size could lead to embolization of wider areas of the liver.
We followed the method of Garin et al. [24] to obtain the TNR in the tumor and normal parenchyma. To overcome the subjectivity of measuring the normal parenchymal count, we applied two or three VOIs in the normal liver parenchyma at the proximity of each tumor and compared weighted kappa values derived from two independent researchers. The kappa values for TNR-yp and TNR-ms are 0.710 and 0.764, respectively, which showed substantial agreement.
The TNR values of 90 Y PET/CT showed weak positive correlation with the tumor volume measured by using angiographic CT (rho=0.230, p value=0.0412). This means that more microspheres may accumulate in the larger tumors. In smaller tumors, however, due to the partial volume effect, the radioactivity could be measured to be lower than the actual value, and this could lead to a lower TNR value.
The pretreatment dosimetry during the procedure of 90 Y radioembolization is important for safe and adequate treatment as well as predicting the occurrence of complications and treatment response. Tc MAA is the only clinically available surrogate marker for distribution of microsphere, we recommend measurement of tumorous uptake using 90 Y PET/CT should be included routinely in the posttherapeutic evaluation.
